Treatment Trial of Subclinical Hypothyroidism in Down Syndrome

Status Completed

Clinical Trial Summary

The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic health and quality of life.

Clinical Trial Description

The American Academy of Pediatrics (AAP) recommends yearly screening of thyroid studies in DS. Clinical experience suggests that thyroid stimulating hormone (TSH) concentrations in the subclinical hypothyroid range (5-10 milli international units(mIU/L)) are not uncommon in DS, but the benefits and risks of treating SCH in the DS population are not known. In adults, SCH has been associated with increased cardiometabolic risk (CMR) and individuals with DS may be at increased cardiometabolic risk as well.

Data in children with SCH are limited. Despite the recommendations to screen for thyroid dysfunction, evidence to guide management of elevated TSH in children with DS is equally sparse. In non-DS children, TSH>4.65 mIU/L was associated with lower HDL. One year of levothyroxine treatment in short children with subclinical hypothyroidism and short stature improved growth velocity. Left ventricular (LV) function and LV mass (by echocardiography) was not different in 16 children with DS and subclinical hypothyroidism (TSH>6.5 mIU/L; mean TSH = 7.8 mIU/L) vs. 25 children with DS and normal TSH. However, these findings may be limited by the small sample size. An intervention study of 7 subjects age 2-42 years with DS and hypothyroidism, defined as low T4 and normal or elevated TSH (0.2-18.9 mIU/L) on 8 weeks of levothyroxine treatment did not improve developmental or functional outcomes. Anthropometrics and CMR factors were not examined. In contrast, increased TSH in the absence of overt congenital hypothyroidism is common in neonates with DS and prompted a randomized controlled trial (RCT) in 181 neonates with DS. TSH-directed levothyroxine treatment was associated with better growth, weight gain, and motor development after 24 months compared to placebo. These findings highlight that the "asymptomatic" component of subclinical hypothyroidism may have medically-relevant effects. This study will provide potentially clinically relevant preliminary evidence for the treatment of subclinical hypothyroidism in DS. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01832753
Study type	Interventional
Source	Children's Hospital of Philadelphia
Contact
Status	Completed
Phase	N/A
Start date	January 2013
Completion date	October 18, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04854122` - Blood Flow Regulation in Individuals With Down Syndrome - Training Study	N/A
Completed	`NCT04020302` - Self-Monitoring Shopping Intervention	N/A
Recruiting	`NCT01950624` - DS-Connect {TM}: The Down Syndrome Registry
Completed	`NCT04751136` - the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome	Phase 2
Completed	`NCT04767412` - Inspiratory Muscle Training and Physical Fitness in Children With Down Syndrome Randomized Control Trial	N/A
Completed	`NCT04536506` - Bobath and Vojta Therapy for DS	N/A
Not yet recruiting	`NCT04037579` - Protocol for a Non-randomized Survey in Down Syndrome People Who Practice Sports. Self and Observers´ Perception.
Completed	`NCT02882698` - Performance Analysis in Down Syndrome on Mobile Phone	N/A
Completed	`NCT01791725` - A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia	Phase 2
Unknown status	`NCT01975545` - Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21	Phase 2
Completed	`NCT01808508` - Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome	N/A
Terminated	`NCT00754013` - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10	Phase 3
Terminated	`NCT00754052` - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17	Phase 3
Completed	`NCT01313325` - Hippotherapy to Improve the Balance of Children With Movement Disorders	N/A
Completed	`NCT01256112` - Parent Supported Weight Reduction in Down Syndrome	N/A
Completed	`NCT01594346` - Multicenter Vitamin E Trial in Aging Persons With Down Syndrome	Phase 3
Completed	`NCT05343468` - Life Skills Improved in Children With Down Syndrome After Using Assistive Technology	N/A
Suspended	`NCT05755464` - Evaluation of Patients With Down Syndrome Compliance to Dental Therapy
Recruiting	`NCT04022460` - Using Personal Mobile Technology to Identify Obstructive Sleep Apnea in Children With Down Syndrome (UPLOAD)
Completed	`NCT04818437` - Effect of Core Stability Exercises and Balance Training in Postural Control Among Down Syndrome	N/A